Improving the treatment of breathlessness – a phase III randomised, controlled trial of sustained release morphine for the symptomatic treatment of chronic refractory breathlessness. A Palliative Care Clinical Studies Collaborative study

改善呼吸困难的治疗 — 缓释吗啡用于对慢性难治性呼吸困难的对症治疗的 III 期随机对照试验。

• 批准号: nhmrc : 1065571
• 负责人: Dr Nikki Mccaffrey
• 金额: $ 60.19万
• 依托单位: Flinders University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/improving-treatment-breathlessness-collaborative-study/455179
• 关键词: Improving; treatment; breathlessness; phase; III

More than 300000 Australians are chronically short of breath at rest or on minimal exertion despite optimal treatment of the underlying causes of their breathlessness, of whom 70000 cannot leave home. No medication in the world is registered to treat this. There is evidence that regular, low dose morphine safely helps breathlessness. This study will help clinicians adjust doses more effectively and understand whether using an additional medication to reduce anxiety helps relieve breathlessness.

超过30万的澳大利亚人在休息或轻微运动时长期呼吸急促，尽管对他们呼吸急促的根本原因进行了最佳治疗，其中7万人不能离开家。世界上没有注册的药物可以治疗这种疾病。有证据表明，定期，低剂量吗啡安全地帮助呼吸困难。这项研究将帮助临床医生更有效地调整剂量，并了解使用额外的药物来减少焦虑是否有助于缓解呼吸困难。